CAC 40
7 328,54 -17,61 (-0,24 %) Euro Stoxx 50
4 412,62 -5,89 (-0,13 %) Dow Jones
36 245,50 +294,60 (+0,82 %) EUR/USD
1,0872 -0,0013 (-0,12 %) Gold future
2 087,10 -2,60 (-0,12 %) Bitcoin EUR
38 386,39 +2 110,43 (+5,82 %)
MRK Dec 2023 90.000 call
| Clôture précédente | 13,38 |
| Ouverture | 13,55 |
| Offre | 0,00 |
| Vente | 0,00 |
| Prix d’exercice | 90,00 |
| Date d’expiration | 2023-12-15 |
| Var. jour | 13,38 - 13,55 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 152 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
